HomeBNTC • NASDAQ
Benitec Biopharma Inc
add
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 10.19M | 145.85% |
Net income | -9.35M | -118.60% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -10.18M | -147.21% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 103.58M | 632.40% |
Total assets | 105.21M | 601.44% |
Total liabilities | 7.64M | 118.32% |
Total equity | 97.57M | — |
Shares outstanding | 25.60M | — |
Price to book | 4.05 | — |
Return on assets | -27.64% | — |
Return on capital | -29.17% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -9.35M | -118.60% |
Cash from operations | -3.09M | 49.97% |
Cash from investing | -6.00K | 96.65% |
Cash from financing | 28.41M | — |
Net change in cash | 25.30M | 505.99% |
Free cash flow | 60.50K | 101.31% |
Previous close
$15.49
Day range
$15.03 - $16.35
Year range
$5.74 - $16.90
Market cap
388.36M USD
Avg Volume
39.30K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Benitec Biopharma Limited is an Australian biotechnology company founded in 1997. It is engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases using DNA-directed RNA interference technology.
The CSIRO has researched RNAi extensively, developing the small hairpin RNA concept employed in ddRNAi. Benitec Biopharma has an exclusive license to this ddRNAi technology in human therapeutic uses and research. Wikipedia
Founded
1997
Website
Employees
16
